

## References

1. Kato H, Tateishi K, Fujiwara H, et al. MNX1-HNF1B Axis Is Indispensable for Intraductal Papillary Mucinous Neoplasm Lineages. *Gastroenterology* 2022;162:1272-1287.e16.
2. Omori Y, Ono Y, Morikawa T, et al. Serine/Threonine Kinase 11 Plays a Canonical Role in Malignant Progression of KRAS-mutant and GNAS-wild-type Intraductal Papillary Mucinous Neoplasms of the Pancreas. *Ann Surg* 2021 in press.
3. Noë M, Niknafs N, Fischer CG, et al. Genomic characterization of malignant progression in neoplastic pancreatic cysts. *Nat Commun* 2020;11:4085.
4. Chhoda A, Singh S, Sheth AH, et al. Benefit of Extended Surveillance of Low-Risk Pancreatic Cysts After 5-Year Stability: A Systematic Review and Meta-Analysis. *Clin Gastroenterol Hepatol* 2022 in press.
5. Capurso G, Crippa S, Vanella G, et al. Factors Associated With the Risk of Progression of Low-Risk Branch-Duct Intraductal Papillary Mucinous Neoplasms. *JAMA Netw Open* 2020;3:e2022933.
6. Oyama H, Tada M, Takagi K, et al. Long-term Risk of Malignancy in Branch-Duct Intraductal Papillary Mucinous Neoplasms. *Gastroenterology* 2020;158:226-237.e5.
7. Pergolini I, Sahora K, Ferrone CR, et al. Long-term Risk of Pancreatic Malignancy in Patients With Branch Duct Intraductal Papillary Mucinous Neoplasm in a Referral Center. *Gastroenterology* 2017;153:1284-1294.e1.
8. Mukewar S, de Pretis N, Aryal-Khanal A, et al. Fukuoka criteria accurately predict risk for adverse outcomes during follow-up of pancreatic cysts presumed to be intraductal papillary mucinous neoplasms. *Gut* 2017;66:1811-1817.
9. van Huijgevoort NCM, Del Chiaro M, Wolfgang CL, et al. Diagnosis and management of pancreatic cystic neoplasms: current evidence and guidelines. *Nat Rev Gastroenterol Hepatol* 2019;16:676-689.
10. Kim HS, Han Y, Kang JS, et al. Fate of Patients With Intraductal Papillary Mucinous Neoplasms of Pancreas After Resection According to the Pathology and Margin Status: Continuously Increasing Risk of Recurrence Even After Curative Resection Suggesting Necessity of Lifetime Surveillance. *Ann Surg* 2022;276:e231-e238.
11. Hirono S, Shimizu Y, Ohtsuka T, et al. Recurrence patterns after surgical resection of intraductal papillary mucinous neoplasm (IPMN) of the pancreas; a multicenter, retrospective study of 1074 IPMN patients by the Japan Pancreas Society. *J Gastroenterol* 2020;55:86-99.
12. Blackham AU, Doecker MP, Centeno BA, et al. Patterns of recurrence and long-term outcomes in patients who underwent pancreatectomy for intraductal papillary mucinous

neoplasms with high-grade dysplasia: implications for surveillance and future management guidelines. *HPB (Oxford)* 2017;19:603-610.

13. Tanaka M, Fernandez-Del Castillo C, Kamisawa T, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. *Pancreatology* 2017;17:738-753.
14. European Study Group on Cystic Tumours of the Pancreas. European evidence-based guidelines on pancreatic cystic neoplasms. *Gut* 2018;67:789-804.
15. Elta GH, Enestvedt BK, Sauer BG, et al. ACG Clinical Guideline: Diagnosis and Management of Pancreatic Cysts. *Am J Gastroenterol* 2018;113:464-479.
16. Vege SS, Ziring B, Jain R, et al. American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. *Gastroenterology* 2015;148:819-22; quiz12-3.
17. Mizuno S, Isayama H, Nakai Y, et al. Prevalence of Pancreatic Cystic Lesions Is Associated With Diabetes Mellitus and Obesity: An Analysis of 5296 Individuals Who Underwent a Preventive Medical Examination. *Pancreas* 2017;46:801-805.
18. Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. *CA Cancer J Clin* 2022;72:7-33.
19. Ecker BL, Dickinson SM, Saadat LV, et al. Segmental vs. Diffuse Main Duct Intraductal Papillary Mucinous Neoplasm: Examination of Main Pancreatic Duct Morphology and Implications for Malignancy Risk and Extent of Surgical Resection. *Ann Surg* 2022 in press.
20. Jung HS, Han Y, Kang JS, et al. Prediction of malignancy in main duct or mixed-type intraductal papillary mucinous neoplasms of the pancreas. *J Hepatobiliary Pancreat Sci* 2022;29:1014-1024.
21. Del Chiaro M, Beckman R, Ateeb Z, et al. Main Duct Dilatation Is the Best Predictor of High-grade Dysplasia or Invasion in Intraductal Papillary Mucinous Neoplasms of the Pancreas. *Ann Surg* 2020;272:1118-1124.
22. Marchegiani G, Andrianello S, Morbin G, et al. Importance of main pancreatic duct dilatation in IPMN undergoing surveillance. *Br J Surg* 2018;105:1825-1834.
23. Hamada T, Oyama H, Nakai Y, et al. ABO Blood Group and Risk of Pancreatic Carcinogenesis in Intraductal Papillary Mucinous Neoplasms. *Cancer Epidemiol Biomarkers Prev* 2021;30:1020-1028.
24. Fischer CG, Wood LD. From somatic mutation to early detection: insights from molecular characterization of pancreatic cancer precursor lesions. *J Pathol* 2018;246:395-404.

25. Patra KC, Bardeesy N, Mizukami Y. Diversity of Precursor Lesions For Pancreatic Cancer: The Genetics and Biology of Intraductal Papillary Mucinous Neoplasm. *Clin Transl Gastroenterol* 2017;8:e86.
26. Fahrman JF, Schmidt CM, Mao X, et al. Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection. *Gastroenterology* 2021;160:1373-1383.e6.
27. Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* 2021;19:439-457.
28. Kawakubo K, Tada M, Isayama H, et al. Incidence of extrapancreatic malignancies in patients with intraductal papillary mucinous neoplasms of the pancreas. *Gut* 2011;60:1249-53.
29. Michihata N, Suzuki T, Yoshikawa T, et al. Association between intravenous immunoglobulin dose and outcomes in patients with acute Kawasaki disease. *Eur J Pediatr* 2022;181:3607-3615.
30. Hamada T, Yasunaga H, Nakai Y, et al. Continuous regional arterial infusion for acute pancreatitis: a propensity score analysis using a nationwide administrative database. *Crit Care* 2013;17:R214.
31. Aziz H, Acher AW, Krishna SG, et al. Comparison of Society Guidelines for the Management and Surveillance of Pancreatic Cysts: A Review. *JAMA Surg* 2022;157:723-730.
32. Aronsson L, Ansari D, Andersson B, et al. Intraductal papillary mucinous neoplasms of the pancreas - a cost-effectiveness analysis of management strategies for the branch-duct subtype. *HPB (Oxford)* 2018;20:1206-1214.
33. Huang ES, Gazelle GS, Hur C. Consensus guidelines in the management of branch duct intraductal papillary mucinous neoplasm: a cost-effectiveness analysis. *Dig Dis Sci* 2010;55:852-60.
34. Das A, Ngamruengphong S, Nagendra S, et al. Asymptomatic pancreatic cystic neoplasm: a cost-effectiveness analysis of different strategies of management. *Gastrointest Endosc* 2009;70:690-699.e6.
35. Weinberg BM, Spiegel BM, Tomlinson JS, et al. Asymptomatic pancreatic cystic neoplasms: maximizing survival and quality of life using Markov-based clinical nomograms. *Gastroenterology* 2010;138:531-40.
36. Singhi AD, Wood LD. Early detection of pancreatic cancer using DNA-based molecular approaches. *Nat Rev Gastroenterol Hepatol* 2021;18:457-468.
37. Park HJ, Shin K, You MW, et al. Deep Learning-based Detection of Solid and Cystic Pancreatic Neoplasms at Contrast-enhanced CT. *Radiology* 2023;306:140-149.

38. Mukherjee S, Patra A, Khasawneh H, et al. Radiomics-based Machine-learning Models Can Detect Pancreatic Cancer on Prediagnostic Computed Tomography Scans at a Substantial Lead Time Before Clinical Diagnosis. *Gastroenterology* 2022;163:1435-1446.e3.
39. Takeda T, Sasaki T, Inoue Y, et al. Early-onset pancreatic cancer: Clinical characteristics and survival outcomes. *Pancreatology* 2022;22:507-515.
40. Habib JR, Kinny-Köster B, Amini N, et al. Predictors, Patterns, and Timing of Recurrence Provide Insight into the Disease Biology of Invasive Carcinomas Arising in Association with Intraductal Papillary Mucinous Neoplasms. *J Gastrointest Surg* 2022;26:2311-2320.
41. Tsujimae M, Masuda A, Ikegawa T, et al. Comprehensive Analysis of Molecular Biologic Characteristics of Pancreatic Ductal Adenocarcinoma Concomitant with Intraductal Papillary Mucinous Neoplasm. *Ann Surg Oncol* 2022;29:4924-4934.
42. Suzuki T, Masugi Y, Inoue Y, et al. KRAS variant allele frequency, but not mutation positivity, associates with survival of patients with pancreatic cancer. *Cancer Sci* 2022;113:3097-3109.
43. Hamada T, Nakai Y, Isayama H, et al. Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer. *Eur J Cancer* 2016;65:11-20.
44. Zhang XW, Ma YX, Sun Y, et al. Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis. *Target Oncol* 2017;12:309-321.
45. Petito LC, García-Albéniz X, Logan RW, et al. Estimates of Overall Survival in Patients With Cancer Receiving Different Treatment Regimens: Emulating Hypothetical Target Trials in the Surveillance, Epidemiology, and End Results (SEER)-Medicare Linked Database. *JAMA Netw Open* 2020;3:e200452.
46. Yoshioka R, Yasunaga H, Hasegawa K, et al. Impact of hospital volume on hospital mortality, length of stay and total costs after pancreaticoduodenectomy. *Br J Surg* 2014;101:523-9.
47. Wang M, Li D, Chen R, et al. Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours: a multicentre, open-label, randomised controlled trial. *Lancet Gastroenterol Hepatol* 2021;6:438-447.
48. Fu Y, Qiu J, Yu Y, et al. Meta-analysis of robotic versus open pancreaticoduodenectomy in all patients and pancreatic cancer patients. *Front Surg* 2022;9:989065.
49. Smits FJ, Verweij ME, Daamen LA, et al. Impact of Complications After Pancreatoduodenectomy on Mortality, Organ Failure, Hospital Stay, and Readmission: Analysis of a Nationwide Audit. *Ann Surg* 2022;275:e222-e228.

50. Beger HG, Poch B, Mayer B, et al. New Onset of Diabetes and Pancreatic Exocrine Insufficiency After Pancreaticoduodenectomy for Benign and Malignant Tumors: A Systematic Review and Meta-analysis of Long-term Results. *Ann Surg* 2018;267:259-270.
51. Sharib J, Esserman L, Koay EJ, et al. Cost-effectiveness of consensus guideline based management of pancreatic cysts: The sensitivity and specificity required for guidelines to be cost-effective. *Surgery* 2020;168:601-609.
52. Coyle D, Ko YJ, Coyle K, et al. Cost-Effectiveness Analysis of Systemic Therapies in Advanced Pancreatic Cancer in the Canadian Health Care System. *Value Health* 2017;20:586-592.
53. Gharaibeh M, McBride A, Alberts DS, et al. Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer. *Pharmacoeconomics* 2018;36:1333-1343.
54. Gharaibeh M, McBride A, Alberts DS, et al. Economic Evaluation for USA of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer. *Pharmacoeconomics* 2018;36:1273-1284.
55. Morimoto K, Moriwaki K, Kaneyasu T, et al. Cost-Effectiveness of Nab-Paclitaxel and Gemcitabine Versus Gemcitabine Monotherapy for Patients with Unresectable Metastatic Pancreatic Cancer in Japan. *Value Health Reg Issues* 2022;28:54-60.
56. van Dijk SM, Heerkens HD, Tseng DSJ, et al. Systematic review on the impact of pancreatoduodenectomy on quality of life in patients with pancreatic cancer. *HPB (Oxford)* 2018;20:204-215.
57. van der Gaag NA, Berkhemer OA, Sprangers MA, et al. Quality of life and functional outcome after resection of pancreatic cystic neoplasm. *Pancreas* 2014;43:755-61.
58. Shah KP, Baugh KA, Brubaker LS, et al. Long-Term Assessment of Pancreatic Function After Pancreatectomy for Cystic Neoplasms. *J Surg Res* 2020;247:547-555.
59. Wundsam HV, Rösch CS, Kirchweger P, et al. Long-Term Quality of Life after Pancreatic Surgery for Intraductal Papillary Mucinous Neoplasm. *Eur Surg Res* 2021;62:80-87.
60. Fong ZV, Alvino DM, Castillo CF, et al. Health-related Quality of Life and Functional Outcomes in 5-year Survivors After Pancreaticoduodenectomy. *Ann Surg* 2017;266:685-692.
61. Laitinen I, Sand J, Peromaa P, et al. Quality of life in patients with pancreatic ductal adenocarcinoma undergoing pancreaticoduodenectomy. *Pancreatology* 2017;17:445-450.

62. Shaw K, Thomas AS, Rosario VL, et al. Long-term quality of life and global health following pancreatic surgery for benign and malignant pathologies. *Surgery* 2021;170:917-924.
63. Latenstein AEJ, Blonk L, Tjahjadi NS, et al. Long-term quality of life and exocrine and endocrine insufficiency after pancreatic surgery: a multicenter, cross-sectional study. *HPB (Oxford)* 2021;23:1722-1731.
64. Moris D, Rushing C, McCracken E, et al. Quality of Life Associated with Open vs Minimally Invasive Pancreaticoduodenectomy: A Prospective Pilot Study. *J Am Coll Surg* 2022;234:632-644.
65. Scholten L, Latenstein AEJ, van Eijck C, et al. Outcome and long-term quality of life after total pancreatectomy (PANORAMA): a nationwide cohort study. *Surgery* 2019;166:1017-1026.
66. Kristensen A, Vagnildhaug OM, Grønberg BH, et al. Does chemotherapy improve health-related quality of life in advanced pancreatic cancer? A systematic review. *Crit Rev Oncol Hematol* 2016;99:286-98.
67. Al-Batran SE, Hofheinz RD, Reichart A, et al. Quality of life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: Real-life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registry. *Int J Cancer* 2021;148:1478-1488.
68. Amin S, Joo S, Nolte S, et al. Health-related quality of life scores of metastatic pancreatic cancer patients responsive to first line chemotherapy compared to newly derived EORTC QLQ-C30 reference values. *BMC Cancer* 2022;22:563.
69. Sanders GD, Neumann PJ, Basu A, et al. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. *Jama* 2016;316:1093-103.